# Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma

> **NCT03837808** · PHASE3 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 384 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
- Nasopharyngeal Diseases
- Head and Neck Neoplasm

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT03837808
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-11
- **Primary completion:** 2024-02-11
- **Final completion:** 2024-02-11
- **Target enrollment:** 384 (ESTIMATED)
- **Last updated:** 2022-11-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03837808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03837808, "Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03837808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*